Grekas D, Alivanis P, Karamouzis M, Pyrpasopoulos M, Tourkantonis A
First Medical Department and Renal Unit, University Hospital AHEPA, Thessaloniki, Greece.
Artif Organs. 1989 Oct;13(5):422-6. doi: 10.1111/j.1525-1594.1989.tb01551.x.
Twelve patients, 8 male and 4 female, aged from 26 to 70 years were studied. They were on hemodialysis (HD) 4 h three times weekly with cuprophan hollow fiber dialyzers (Gambro 120M) and dialysate containing 35 mEq/L of acetate. The study compares two random HD sessions on each patient. Sixty minutes prior to one random session a placebo was administered orally, and prior to another random session piracetam was given at a dose of 8 g. Heparin dosage was not reduced during HD using QB 200 ml, QD 500 ml, and no ultrafiltration. Blood samples for leukocyte and platelet counts, serum C3, arterial paO2 and paCO2, thromboxane-B2 (TxB2), and beta-thromboglobulin (beta-TG) were taken from the arterial line before and at 15, 60, and 240 min during HD. Leukopenia at 15 min of HD was found to be less severe (p less than 0.01) in the piracetam study than in the placebo, whereas platelet count did not change. Serum C3 was slightly increased in both studies. Arterial oxygen was preserved close to the initial levels by piracetam (91.66 mm Hg versus 81.08, p less than 0.01 at 60 min, and 93.08 versus 80.17 mm Hg, p less than 0.01 at 240 min of HD sessions) but paCO2 did not change significantly. TxB2 increased less with piracetam in comparison to placebo (p less than 0.01 or p less than 0.001), but beta-TG was reduced significantly by piracetam at any time during HD (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
对12例患者进行了研究，其中男性8例，女性4例，年龄在26至70岁之间。他们每周使用铜仿中空纤维透析器（Gambro 120M）进行3次血液透析（HD），每次4小时，透析液中醋酸盐含量为35 mEq/L。该研究比较了每位患者的两次随机HD治疗。在一次随机治疗前60分钟口服安慰剂，在另一次随机治疗前给予8克剂量的吡拉西坦。使用QB 200 ml、QD 500 ml进行HD期间肝素剂量未减少，且未进行超滤。在HD前以及HD期间的15、60和240分钟从动脉管路采集血液样本，用于白细胞和血小板计数、血清C3、动脉血氧分压（paO2）和二氧化碳分压（paCO2）、血栓素B2（TxB2）以及β-血小板球蛋白（β-TG）的检测。发现在HD 15分钟时，吡拉西坦研究中的白细胞减少程度比安慰剂组轻（p<0.01），而血小板计数未发生变化。两项研究中血清C3均略有升高。吡拉西坦使动脉血氧接近初始水平得以维持（HD治疗60分钟时为91.66 mmHg对81.08，p<0.01；HD治疗240分钟时为93.08对80.17 mmHg，p<0.01），但paCO2无显著变化。与安慰剂相比，吡拉西坦使TxB2升高幅度较小（p<0.01或p<0.001），但在HD期间的任何时间，吡拉西坦均可显著降低β-TG（p<0.001）。（摘要截短至250字）
